Crinetics to Present Latest Data on PALSONIFY™ and Atumelnant at ENDO 2025

Another Innovation to be Launched at ENDO 2025

Image Credits: The Manila Times

Announcement

Crinetics Pharmaceuticals, Inc. is ready to showcase eight abstracts from its clinical development programs, and its oral presentations involve an investigational drug candidate, atumelnant, and PALSONIFY™ (paltusotine) at the Endocrine Society’s annual meeting, ENDO 2025, from 12th to 15th July 2025, in San Francisco, California. ENDO 2025 platform will have a chance and opportunity to showcase new talent and innovations that will be entrance into the healthcare market. Crinetics, with the help of its developmental programs, is building a strong presentation that will reflect in a certain way, contributing to the vast healthcare sector. The FDA clearance will stimulate the overall presentation.

Presentation

The four abstracts will reflect the results from the PALSONIFY development program, as well as the oral presentation highlighting open-label extension data from the registrational phase 3 PATHFNDR trials. The presentation will introduce a long-lasting safety and control symptom in individuals with acromegaly, which shifted from injectable somatostatin receptor ligands (SRLs) to oral PALSONIFY (once daily). Additionally, Crinetics will showcase three poster presentations. One of the presentations evaluates symptom stability in acromegaly, identifying patient-reported outcomes from PATHFNDR-1 and 2 and other outcomes related to PATHFNDR-2 open-label extension data. These abstracts show PALSONIFY’s continuity to be tolerable, enabling controlled symptomatic diseases and consistency in biochemical parameters.

The company will also introduce three abstracts from the Crinetics atumelnant clinical development program, which consist of oral presentations of phase 2 trial results in congenital adrenal hyperplasia (CAH). The presentation also aims to reduce adrenal volume and potent 11-oxygenated androgens, a phase 2 trial participant's (biomarker).

Apart from the two lead programs, the company will represent new data from its previous pipeline, such as data from CRN12755 for orbitopathy and Graves’ hyperthyroidism. PALSONIFY has recently received approval US FDA.

Views and Statements

Founder and Chief Executive Officer of Crinetics, Phd, Scott Struthers said, “ENDO 2025 will be a meaningful event and moment for our company that will strengthen our mission to become a primary endocrine-focused leading pharmaceutical company. We are excited about our lead investigational candidate, PALSONIFY, for acromegaly. This will be a long-term dataset to be presented, supporting the same consistency and durability of profile as earlier pivotal trials.” Further, “The convincing phase 2 trial results from new data and atumelnant in CAH. The data has been fetched from our early-stage development programs, elaborating Crinetics’ pipeline capability to address significant unmet needs.”